Exacerbated autoimmunity in the absence of TLR9 in MRL.Faslpr mice depends on Ifnar1

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 3889-3894

  Nickerson, Kevin M ^a   Cullen, Jaime L ^a   Kashgarian, Michael ^a   Shlomchik, Mark J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; IFNAR1 PROTEIN; INTERFERON; NEUTROPHIL CYTOPLASMIC ANTIBODY; NUCLEOSOME ANTIBODY; RECEPTOR SUBUNIT; RNA ANTIBODY; SM ANTIBODY; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; KIDNEY DISEASE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; HEP G2 CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED MRL LPR; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTOR, INTERFERON ALPHA-BETA; TOLL-LIKE RECEPTOR 9;

EID: 84875986912     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203525     Document Type: Article

References (34)

1. Fairhurst, A.-M., A. E. Wandstrat, and E. K. Wakeland. 2006. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv. Immunol. 92: 1-69.
2. Kirou, K. A., C. Lee, S. George, K. Louca, M. G. E. Peterson, and M. K. Crow. 2005. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52: 1491-1503.
3. Nowling, T. K., and G. S. Gilkeson. 2011. Mechanisms of tissue injury in lupus nephritis. Arthritis Res. Ther. 13: 250.
4. Christensen, S. R., M. Kashgarian, L. Alexopoulou, R. A. Flavell, S. Akira, and M. J. Shlomchik. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202: 321-331.
5. Christensen, S. R., J. Shupe, K. Nickerson, M. Kashgarian, R. A. Flavell, and M. J. Shlomchik. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428.
6. Nickerson, K. M., S. R. Christensen, J. Shupe, M. Kashgarian, D. Kim, K. Elkon, and M. J. Shlomchik. 2010. TLR9 regulates TLR7- and MyD88-dependent au-toantibody production and disease in a murine model of lupus. J. Immunol. 184: 1840-1848.
7. Lartigue, A., P. Courville, I. Auquit, A. François, C. Arnoult, F. Tron, D. Gilbert, and P. Musette. 2006. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J. Immunol. 177: 1349-1354.
8. Santiago-Raber, M.-L., I. Dunand-Sauthier, T. Wu, Q.-Z. Li, S. Uematsu, S. Akira, W. Reith, C. Mohan, B. L. Kotzin, and S. Izui. 2010. Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J. Autoimmun. 34: 339-348.
9. Stoehr, A. D., C. T. Schoen, M. M. M. Mertes, S. Eiglmeier, V. Holecska, A. K. Lorenz, T. Schommartz, A.-L. Schoen, C. Hess, A. Winkler, et al. 2011. TLR9 in peritoneal B-1b cells is essential for production of protective self-reactive IgM to control Th17 cells and severe autoimmunity. J. Immunol. 187: 2953-2965.
10. Yu, P., U. Wellmann, S. Kunder, L. Quintanilla-Martinez, L. Jennen, N. Dear, K. Amann, S. Bauer, T. H. Winkler, and H. Wagner. 2006. Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int. Immunol. 18: 1211-1219.
11. Lichtman, E. I., S. M. Helfgott, and M. A. Kriegel. 2012. Emerging therapies for systemic lupus erythematosus-focus on targeting interferon-alpha. Clin. Immunol. 143: 210-221.
12. Niewold, T. B. 2011. Interferon alpha as a primary pathogenic factor in human lupus. J. Interferon Cytokine Res. 31: 887-892.
13. Agrawal, H., N. Jacob, E. Carreras, S. Bajana, C. Putterman, S. Turner, B. Neas, A. Mathian, M. N. Koss, W. Stohl, et al. 2009. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J. Immunol. 183: 6021-6029.
14. Nacionales, D. C., K. M. Kelly-Scumpia, P. Y. Lee, J. S. Weinstein, R. Lyons, E. Sobel, M. Satoh, and W. H. Reeves. 2007. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56: 3770-3783.
15. Braun, D., P. Geraldes, and J. Demengeot. 2003. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20: 15-25.
16. Santiago-Raber, M.-L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197: 777-788.
17. Thibault, D. L., K. L. Graham, L. Y. Lee, I. Balboni, P. J. Hertzog, and P. J. Utz. 2009. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. Arthritis Res. Ther. 11: R112.
18. Jørgensen, T. N., E. Roper, J. M. Thurman, P. Marrack, and B. L. Kotzin. 2007. Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. Genes Immun. 8: 653-662.
19. Hron, J. D., and S. L. Peng. 2004. Type I IFN protects against murine lupus. J. Immunol. 173: 2134-2142.
20. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
21. Campbell, A. M., M. Kashgarian, and M. J. Shlomchik. 2012. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl. Med. 4: 157ra141.
22. Blanco, F., J. Kalsi, and D. A. Isenberg. 1991. Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases. Clin. Exp. Immunol. 86: 66-70.
23. Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, and F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148: 1198-1215.
24. Kanauchi, H., F. Furukawa, and S. Imamura. 1991. Characterization of cutaneous infiltrates in MRL/lpr mice monitored from onset to the full development of lupus erythematosus-like skin lesions. J. Invest. Dermatol. 96: 478-483.
25. Furukawa, F., H. Tanaka, K. Sekita, T. Nakamura, Y. Horiguchi, and Y. Hamashima. 1984. Dermatopathological studies on skin lesions of MRL mice. Arch. Dermatol. Res. 276: 186-194.
26. Rawlings, D. J., M. A. Schwartz, S. W. Jackson, and A. Meyer-Bahlburg. 2012. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12: 282-294.
27. Lau, C. M., C. Broughton, A. S. Tabor, S. Akira, R. A. Flavell, M. J. Mamula, S. R. Christensen, M. J. Shlomchik, G. A. Viglianti, I. R. Rifkin, and A. Marshak-Rothstein. 2005. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202: 1171-1177.
28. Leadbetter, E. A., I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607.
29. Cash, H., M. Relle, J. Menke, C. Brochhausen, S. A. Jones, N. Topley, P. R. Galle, and A. Schwarting. 2010. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythe-matosus. J. Rheumatol. 37: 60-70.
30. Schwarting, A., T. Wada, K. Kinoshita, G. Tesch, and V. R. Kelley. 1998. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 161: 494-503.
31. Rubtsov, A. V., K. Rubtsova, J. W. Kappler, and P. Marrack. 2010. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun. Rev. 9: 494-498.
32. Kiefer, K., M. A. Oropallo, M. P. Cancro, and A. Marshak-Rothstein. 2012. Role of type I interferons in the activation of autoreactive B cells. Immunol. Cell Biol. 90: 498-504.
33. Barrat, F. J., and R. L. Coffman. 2008. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol. Rev. 223: 271-283.
34. Green, N. M., A. Laws, K. Kiefer, L. Busconi, Y.-M. Kim, M. M. Brinkmann, E. H. Trail, K. Yasuda, S. R. Christensen, M. J. Shlomchik, et al. 2009. Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop. J. Immunol. 183: 1569-1576.